PURPOSE: There is considerable variation in the use of HLA-matched related bone marrow transplantation (BMT) for the treatment of pediatric patients with newly diagnosed acute myeloid leukemia (AML). Some oncologists have argued that BMT should be offered to most patients in first complete remission (CR). Others have maintained that transplantation in first remission should be reserved for patients with high-risk disease. We performed this study to determine how disease risk influences the efficacy of BMT. METHODS: We combined data from four cooperative group clinical trials: Pediatric Oncology Group 8821, Children's Cancer Group (CCG) 2891, CCG 2961, and Medical Research Council 10. Using cytogenetics and the percentage of marrow blasts after the first course of chemotherapy, patients were stratified into favorable, intermediate, and poor-risk disease groups. Patients who could not be risk classified were analyzed separately. Outcomes for patients assigned to BMT and for patients assigned to chemotherapy alone were compared. RESULTS: The data set included 1,373 pediatric patients with AML in first CR. In the intermediate-risk group, the estimated disease-free survival at 8 years for patients who did not undergo transplantation was 39% +/- 5% (2 SE), whereas it was 58% +/- 7% for BMT patients. The estimated overall survival for patients who did not undergo transplantation was 51% +/- 5%, whereas it was 62% +/- 7% for BMT patients. Both differences were significant (P < .01). There were no significant differences for survival in the other two risk groups or in the non-risk-stratified patients. CONCLUSION: Our study indicates that HLA-matched related BMT is an effective treatment for pediatric patients with intermediate-risk AML in first CR.
PURPOSE: There is considerable variation in the use of HLA-matched related bone marrow transplantation (BMT) for the treatment of pediatric patients with newly diagnosed acute myeloid leukemia (AML). Some oncologists have argued that BMT should be offered to most patients in first complete remission (CR). Others have maintained that transplantation in first remission should be reserved for patients with high-risk disease. We performed this study to determine how disease risk influences the efficacy of BMT. METHODS: We combined data from four cooperative group clinical trials: Pediatric Oncology Group 8821, Children's Cancer Group (CCG) 2891, CCG 2961, and Medical Research Council 10. Using cytogenetics and the percentage of marrow blasts after the first course of chemotherapy, patients were stratified into favorable, intermediate, and poor-risk disease groups. Patients who could not be risk classified were analyzed separately. Outcomes for patients assigned to BMT and for patients assigned to chemotherapy alone were compared. RESULTS: The data set included 1,373 pediatric patients with AML in first CR. In the intermediate-risk group, the estimated disease-free survival at 8 years for patients who did not undergo transplantation was 39% +/- 5% (2 SE), whereas it was 58% +/- 7% for BMT patients. The estimated overall survival for patients who did not undergo transplantation was 51% +/- 5%, whereas it was 62% +/- 7% for BMT patients. Both differences were significant (P < .01). There were no significant differences for survival in the other two risk groups or in the non-risk-stratified patients. CONCLUSION: Our study indicates that HLA-matched related BMT is an effective treatment for pediatric patients with intermediate-risk AML in first CR.
Authors: B E S Gibson; K Wheatley; I M Hann; R F Stevens; D Webb; R K Hills; S S N De Graaf; C J Harrison Journal: Leukemia Date: 2005-12 Impact factor: 11.528
Authors: S O Lie; J Abrahamsson; N Clausen; E Forestier; H Hasle; L Hovi; G Jonmundsson; L Mellander; M A Siimes; M Yssing; B Zeller; G Gustafsson Journal: Leukemia Date: 2005-12 Impact factor: 11.528
Authors: David Becton; Gary V Dahl; Yaddanapudi Ravindranath; Myron N Chang; Fred G Behm; Susana C Raimondi; David R Head; Kimo C Stine; Norman J Lacayo; Branimir Ivan Sikic; Robert J Arceci; Howard Weinstein Journal: Blood Date: 2005-10-27 Impact factor: 22.113
Authors: W G Woods; S Neudorf; S Gold; J Sanders; J D Buckley; D R Barnard; K Dusenbery; J DeSwarte; D C Arthur; B J Lange; N L Kobrinsky Journal: Blood Date: 2001-01-01 Impact factor: 22.113
Authors: A Pession; R Rondelli; G Basso; C Rizzari; A M Testi; F Fagioli; P De Stefano; F Locatelli Journal: Leukemia Date: 2005-12 Impact factor: 11.528
Authors: Beverly J Lange; Franklin O Smith; James Feusner; Dorothy R Barnard; Patricia Dinndorf; Stephen Feig; Nyla A Heerema; Carola Arndt; Robert J Arceci; Nita Seibel; Margie Weiman; Kathryn Dusenbery; Kevin Shannon; Sandra Luna-Fineman; Robert B Gerbing; Todd A Alonzo Journal: Blood Date: 2007-11-13 Impact factor: 22.113
Authors: Y Ravindranath; A M Yeager; M N Chang; C P Steuber; J Krischer; J Graham-Pole; A Carroll; S Inoue; B Camitta; H J Weinstein Journal: N Engl J Med Date: 1996-05-30 Impact factor: 91.245
Authors: Jan-Henning Klusmann; Dirk Reinhardt; Martin Zimmermann; Bernhard Kremens; Josef Vormoor; Michael Dworzak; Ursula Creutzig; Thomas Klingebiel Journal: Haematologica Date: 2011-09-20 Impact factor: 9.941
Authors: G Michel; R Cunha; A Ruggeri; T A O'Brien; H Bittencourt; J H Dalle; F Locatelli; A P Iori; M Mauad; C Oudin; F Giannotti; F Volt; E Gluckman; P Bader; V Rocha Journal: Leukemia Date: 2015-09-15 Impact factor: 11.528
Authors: Soheil Meshinchi; Stephen P Hunger; Richard Aplenc; Peter C Adamson; J Milburn Jessup Journal: Clin Cancer Res Date: 2012-03-15 Impact factor: 12.531
Authors: A-L Alloin; G Leverger; J-H Dalle; C Galambrun; Y Bertrand; A Baruchel; A Auvrignon; V Gandemer; C Ragu; A Loundou; C Bilhou-Nabera; M Lafage-Pochitaloff; N Dastugue; B Nelken; C Jubert; F Rialland; G Plat; C Pochon; J-P Vannier; P-S Rohrlich; J Kanold; P Lutz; A Sirvent; C Oudin; W Cuccuini; G Michel Journal: Bone Marrow Transplant Date: 2016-12-12 Impact factor: 5.483
Authors: Jessica A Pollard; Todd A Alonzo; Robert B Gerbing; Phoenix A Ho; Rong Zeng; Yaddanapudi Ravindranath; Gary Dahl; Norman J Lacayo; David Becton; Myron Chang; Howard J Weinstein; Betsy Hirsch; Susana C Raimondi; Nyla A Heerema; William G Woods; Beverly J Lange; Craig Hurwitz; Robert J Arceci; Jerald P Radich; Irwin D Bernstein; Michael C Heinrich; Soheil Meshinchi Journal: Blood Date: 2010-01-07 Impact factor: 22.113